| |
|
|
|
|
|
 |
| |
|
ÄÉÅäÇÁ·Î°Ö(ÄÉÅäÇÁ·ÎÆæ¸®½Å) KETOPROGEL
|
|
ÀϹÝÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
643201050[A06751351]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1g(2016.10.01)(ÇöÀç¾à°¡)
\48 ¿ø/1g(2014.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
ÀüÁú ±ÕµîÇÑ ¹«»öÅõ¸íÀÇ °ÖÁ¦
[Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
50mg¡¿50g¡¿1EA |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 50±×·¥ |
1 °³ |
Æ©ºê |
8806432010509 |
8806432010516 |
|
|
| ÁÖ¼ººÐÄÚµå |
179802CCM
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
È¿´ÉÈ¿°ú
(°ÖÁ¦)
´ÙÀ½ Áúȯ ¹× Áõ»óÀÇ ÁøÅë¼Ò¿° : ÅðÇ༺°üÀý¿°(°ñ°üÀý¿°), ¾î±ú°üÀýÁÖÀ§¿°, °Ç°ÇÃÊ¿°, °ÇÁÖÀ§¿°, »ó¿Ï°ñ»ó°ú¿°(Å״Ͻº ¿¤º¸¿ìµî), ±ÙÀ°Åë, ¿Ü»óÈÄÀÇ Á¾Ã¢µ¿Åë
[Ketoprofen lysinate]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:179802CCM ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
¿ë¹ý¿ë·®
(°ÖÁ¦)
1ÀÏ 2 - 3ȸ ȯºÎ¿¡ ¹Ù¸£°í Àß ½º¸çµéµµ·Ï °¡º±°Ô ¹®Áö¸¥´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à ¹× ÀÌ ¾à ¼ººÐ¿¡ °ú¹ÎÁõ ¹× ±¤°ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ¾Æ½ºÇǸ° õ½Ä(ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°ÁøÅëÁ¦ µî¿¡ ÀÇÇÑ Ãµ½Ä¹ßÀÛÀÇ À¯¹ß) ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ(õ½Ä¹ßÀÛÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù)
3) ´ÙÀ½ÀÇ ¾à¹°¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ : Ƽ¾ÆÇÁ·ÎÆæ»ê, Æä³ëÇǺ극ÀÌÆ®, º£ÀÚÇǺ극ÀÌÆ®, ½ÃÇÁ·ÎÇǺ극ÀÌÆ®, ¿Á½Ãº¥Á¸(ÄÉÅäÇÁ·ÎÆæ°ú ±³Â÷°ú¹Î¹ÝÀÀÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù)
4) ÀӽűⰣ 6°³¿ù ÀÌ»óÀÎ ÀӺΠ: ÀӽŸ»±âÀÇ ·§Æ®¿¡ ÀÌ ¾àÀ» °æ±¸Åõ¿©ÇÑ ½ÇÇè¿¡¼ ÅÂÀÚÀÇ µ¿¸ÆÇ÷°ü¼öÃàÀÌ º¸°íµÇ¾ú´Ù. ÀÓ½ÅÈı⿡ Åõ¿©(°æ±¸, ÁÖ»ç, Á÷ÀåÁÖÀÔ)½Ã Áö¼Ó¼º žƼøÈ¯, ÅÂ¾Æ ½ÅºÎÀüÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù.
5) 15¼¼ ¹Ì¸¸ÀÇ ¼Ò¾Æ
¾÷µ¥ÀÌÆ®ÀÏ:2010.04.30/ ¾÷µ¥ÀÌÆ®Á¾·ù:Çã°¡»çÇ׺¯°æÁö½Ã
|
| ½ÅÁßÅõ¿© |
1) ±â°üÁö õ½Ä ȯÀÚ(õ½Ä¹ßÀÛÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù)
2) ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í Àִ ȯÀÚ
3) ÀӺΠ¶Ç´Â ¼öÀ¯ºÎ (¾ÈÀü¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ´ë·® ¶Ç´Â ±¤¹üÀ§¿¡ °ÉÄ£ Àå±â°£ÀÇ »ç¿ëÀº ÇÇÇÑ´Ù.)
¾÷µ¥ÀÌÆ®ÀÏ:2010.04.30/ ¾÷µ¥ÀÌÆ®Á¾·ù:Çã°¡»çÇ׺¯°æÁö½Ã
|
| ÀÌ»ó¹ÝÀÀ |
1) µå¹°°Ô ¼ï, ¾Æ³ªÇʶô½Ã¾ç Áõ»ó(µÎµå·¯±â, È£Èí°ï¶õ, ¾ó±¼ºÎ±â µî °ú¹Î¼ºÀ¯»çÁõ»ó)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù.
2) õ½Ä¹ßÀÛÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¹Ç·Î °Ç¼º ¼öÆ÷À½(°Åǰ¼Ò¸®), õ¸í(¼ûÀ» ½Ù½Ù°Å¸²), È£Èí°ï¶õ µîÀÇ ÃʱâÁõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù. õ½Ä¹ßÀÛÀº ÀÌ ¾à Àû¿ë ÈÄ ¼ö½Ã°£ ³»¿¡ ³ªÅ¸³´Ù.
3) ÇǺΠ: ¶§¶§·Î ¹ßÀû, ¹ßÁø, °¡·Á¿ò, ¼öÆ÷, Áþ¹«¸§, Àڱذ¨ ¹× Á¾Ã¢(ºÎ±â) µîÀÇ Á¢ÃËÇǺο°, ÇǺΰÇÁ¶ ¹× »ö¼ÒÄ§ÂøÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¶ÇÇÑ Á÷»çÀϱ¤(Àڿܼ±)¿¡ ÀÇÇØ ±¤°ú¹ÎÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç ÇǺιßÁøÀÌ Àü½ÅÀ¸·Î È®´ëµÉ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ Áõ»óÀÌ ½ÉÇÑ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù.
4) 1ÁÖÀÏ Á¤µµ »ç¿ëÇÏ°íµµ Áõ»ó°³¼±ÀÌ º¸ÀÌÁö ¾ÊÀ» °æ¿ì »ç¿ëÀ» ÁßÁöÇϰí ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »óÀÇÇÑ´Ù.
¾÷µ¥ÀÌÆ®ÀÏ:2010.04.30/ ¾÷µ¥ÀÌÆ®Á¾·ù:Çã°¡»çÇ׺¯°æÁö½Ã
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Dµî±Þ
(ÀӽŠ3±â Åõ¿©½Ã )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Ketoprofen¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Ketoprofen¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Ketoprofen is a nonsteroidal anti-inflammatory drug with analgesic and antipyretic properties. Its antiinflammatory effects are believed to be due to inhibition of both cylooxygenase-1 (COX-1) and cylooxygenase-2 (COX-2) which leads to the inhibition of prostaglandin synthesis, and leukotriene synthesis, to have antibrady-kinin activity, as well as to have lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
|
| Pharmacology |
Ketoprofen¿¡ ´ëÇÑ Pharmacology Á¤º¸ Ketoprofen is a nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, that is thought to be associated with the inhibition of prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain.
|
| Metabolism |
Ketoprofen¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Ketoprofen¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 99%
|
| Half-life |
Ketoprofen¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 2-2.5 hours
|
| Absorption |
Ketoprofen¿¡ ´ëÇÑ Absorption Á¤º¸ Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.
|
| Pharmacokinetics |
Ketoprofen lysinateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ´ë»ç : °£´ë»ç
- ¹Ý°¨±â : 1-4 ½Ã°£
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : 0.5-2 ½Ã°£
- ¼Ò½Ç : ½Å¹è¼³(60-75%), ÁÖ·Î glucuronide Æ÷ÇÕü·Î ¹è¼³µÊ
|
| Biotransformation |
Ketoprofen¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Ketoprofen¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50=62.4 mg/kg (rat, oral) Adverse effects from overdose include breathing difficulty, coma, convulsions, drowsiness, high blood pressure, kidney failure, low blood pressure, nausea, sluggishness, stomach and intestinal bleeding, stomach pain, vomiting.
|
| Drug Interactions |
Ketoprofen¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Alendronate Increased risk of gastric toxicityMethotrexate The NSAID increases the effect and toxicity of methotrexateCyclosporine Monitor for nephrotoxicityAnisindione The NSAID increases the anticoagulant effectAcenocoumarol The NSAID increases the anticoagulant effectDicumarol The NSAID increases the anticoagulant effectWarfarin The NSAID increases the anticoagulant effect
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Ketoprofen¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with food to reduce irritation, avoid alcohol.
|
| Drug Target |
[Drug Target]
|
| Description |
Ketoprofen¿¡ ´ëÇÑ Description Á¤º¸ An ibuprofen-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis. [PubChem]
|
| Dosage Form |
Ketoprofen¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralSuppository RectalTablet, coated OralTablet, extended release Oral
|
| Drug Category |
Ketoprofen¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Inflammatory Agents, Non-SteroidalCyclooxygenase Inhibitors
|
| Smiles String Canonical |
Ketoprofen¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
|
| Smiles String Isomeric |
Ketoprofen¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@@H](C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
|
| InChI Identifier |
Ketoprofen¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)/f/h18H
|
| Chemical IUPAC Name |
Ketoprofen¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-[3-(benzoyl)phenyl]propanoic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-12-02
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|